The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
 
Tyler F. Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
 
Nikhil V. Kotha
No Relationships to Disclose
 
Hannah Elizabeth Dzimitrowicz
Research Funding - Pfizer (Inst)
 
Dimitrios Makrakis
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Ali Raza Khaki
Stock and Other Ownership Interests - Merck; Sanofi
 
Nicholas I. Simon
No Relationships to Disclose
 
Ariel Ann Nelson
No Relationships to Disclose
 
Dory Freeman
No Relationships to Disclose
 
Tracy L Rose
Research Funding - Bristol-Myers Squibb; GeneCentric; Merck; Roche/Genentech; X4 Pharma
 
Wolfgang Beck
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Matthew I. Milowsky
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)
 
Andrea B. Apolo
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Dyania Health; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Guru P. Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Janssen (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; QED Therapeutics
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)